What is it about?
This pilot clinical study explored whether two simple in vitro blood tests could help predict which patients with early, methotrexate-naïve rheumatoid arthritis would respond to methotrexate, the gold-standard first-line therapy.
Featured Image
Photo by Malcolm Choong 鍾声耀 on Unsplash
Why is it important?
Although larger studies are required to confirm these findings, the general conclusion is clear: early prediction of methotrexate response through peripheral blood tests may soon become a reality. This opens the way for precision medicine approaches in rheumatoid arthritis, reducing delays in effective treatment and sparing patients from unnecessary exposure to ineffective therapies
Perspectives
The encouraging results of this pilot study pave the way for the development of a new predictive diagnostic product that could guide therapeutic decisions in rheumatoid arthritis.
Teresa Diez
Read the Original
This page is a summary of: Precision medicine in rheumatoid arthritis: Evaluation of a new approach to predict clinical response to methotrexate in patients with early rheumatoid arthritis, PLOS One, August 2025, PLOS,
DOI: 10.1371/journal.pone.0329440.
You can read the full text:
Contributors
The following have contributed to this page
